Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial

[1]  Jennifer K. Sun,et al.  Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. , 2019, JAMA ophthalmology.

[2]  Jennifer K. Sun,et al.  Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti–Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial , 2019, JAMA ophthalmology.

[3]  M. Yaseri,et al.  One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema. , 2017, Ophthalmology Retina.

[4]  A. Pinna,et al.  Bromfenac Eyedrops in the Treatment of Diabetic Macular Edema: A Pilot Study , 2017, European journal of ophthalmology.

[5]  A. Ho,et al.  Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. , 2016, American journal of ophthalmology.

[6]  D. Dahlin,et al.  Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. , 2016, Experimental eye research.

[7]  C. Costagliola,et al.  TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY , 2015, Retina.

[8]  M. Yaseri,et al.  Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial , 2015, International Ophthalmology.

[9]  N. Bressler,et al.  TOPICAL NEPAFENEC IN EYES WITH NONCENTRAL DIABETIC MACULAR EDEMA , 2015, Retina.

[10]  Jennifer K. Sun,et al.  Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.

[11]  N. S. Nair,et al.  Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema. , 2015, The Cochrane database of systematic reviews.

[12]  D. Guyton,et al.  Longitudinal comparison of visual acuity as measured by the ETDRS chart and by the potential acuity meter in eyes with macular edema, and its relationship with retinal thickness and sensitivity , 2014, Eye.

[13]  Jinsong Sheng,et al.  Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. , 2014, JAMA ophthalmology.

[14]  C. Costagliola,et al.  A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration , 2013, British Journal of Ophthalmology.

[15]  K. Falavarjani,et al.  Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature , 2013, Eye.

[16]  Jinsong Sheng,et al.  Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. , 2012, Investigative ophthalmology & visual science.

[17]  T. Peto,et al.  A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.

[18]  Jinzi Zhou,et al.  Role of Intravitreal Inflammatory Cytokines and Angiogenic Factors in Proliferative Diabetic Retinopathy , 2012, Current eye research.

[19]  T. Yilmaz,et al.  Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review , 2012, Eye.

[20]  M. Burnier,et al.  Intravitreal Injection of Commercially Available Ketorolac Tromethamine in Eyes with Diabetic Macular Edema Refractory to Laser Photocoagulation , 2011, Current eye research.

[21]  A. Loewenstein,et al.  General Pathophysiology of Macular Edema , 2011, European journal of ophthalmology.

[22]  L. Jampol,et al.  Nonsteroidal anti-inflammatory drugs in ophthalmology. , 2010, Survey of ophthalmology.

[23]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[24]  C. Awh,et al.  VITREOUS NONSTEROIDAL ANTIINFLAMMATORY DRUG CONCENTRATIONS AND PROSTAGLANDIN E2 LEVELS IN VITRECTOMY PATIENTS TREATED WITH KETOROLAC 0.4%, BROMFENAC 0.09%, AND NEPAFENAC 0.1% , 2009, Retina.

[25]  Ronald Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. , 2009, Ophthalmology.

[26]  D. Callanan,et al.  Topical nepafenac in the treatment of diabetic macular edema , 2008, Clinical ophthalmology.

[27]  K. Solomon,et al.  A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery , 2007, Clinical ophthalmology.

[28]  M. Maia,et al.  Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. , 2007, Ophthalmology.

[29]  Jennifer I. Lim,et al.  Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. , 2007, Ophthalmology.

[30]  J. Marshall,et al.  The pathogenesis of edema in diabetic maculopathy. , 1999, Seminars in ophthalmology.

[31]  Rohan J. Shah,et al.  Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. , 2014, JAMA ophthalmology.

[32]  M. Subramanian,et al.  Meta-analysis and review on the effect of bevacizumab in diabetic macular edema , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  Marco A Zarbin,et al.  Diabetic macular edema: pathogenesis and treatment. , 2009, Survey of ophthalmology.

[34]  T. Mimura,et al.  Association of vitreous inflammatory factors with diabetic macular edema. , 2009, Ophthalmology.

[35]  T. Sano,et al.  [Diabetic retinopathy]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[36]  A. Flach.  Nonsteroidal Anti-inflammatory Drugs in Ophthalmology , 1993, International ophthalmology clinics.